MediWound

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

MediWound reports $5M revenue, advances trials and manufacturing capacity

MediWound's Q1 2024 performance reflects solid revenue from NexoBrid, progress on manufacturing, and strategic advancements in clinical trials and FDA interactions.
While facing challenges in profitability and operational expenses, the company's strengths in innovation, market acceptance, and growth opportunities position it for future success.
With a focus on operational excellence and expansion plans, MediWound remains well-positioned to capitalize on market opportunities and drive sustainable growth.

MediWound reports revenue growth but faces profit challenges in Q2 2024

MediWound's Q2 2024 performance showed revenue growth but faced challenges with decreased gross profit and increased losses. Despite liquidity concerns, the company is capitalizing on opportunities in NexoBrid and EscharEx developments. Analyst interest in capacity expansion and trial funding indicates market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

The stock price of Mediwound Ltd (NASDAQ: MDWD) increased by over 15% pre-market. This is why it happened.

MDWD Stock Increases Over 15% Pre-Market: Why It Happened

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD

Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers

MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal

Vericel

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Biologics License Application. The FDA identified issues related to the Chemistry, Manufacturing, and Controls (CMC) section of the application and requested that MediWound provide additional CMC information.

Why Shares Of MediWound And Vericel Fell On Tuesday

Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal in adults with deep partial-thickness or full-thickness burns. The FDA identified issues related to the Chemistry, Manufacturing, and Controls (CMC) section of the application and requested that MediWound provide additional CMC information.

FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop

Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

Aeterna Zentaris

Amarin Corporation Plc

DURECT

Globus Maritime

CarLotz

Intec Parent

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 To Watch This Week

Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study

MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript

First Quarter Revenues of $5.8 Million, an Increase of 32% Year-over-Year

MediWound Reports First Quarter 2021 Financial Results

MediWound (NASDAQ:MDWD) releases its next round of earnings this Wednesday, May 05. Here is Benzinga's essential guide to MediWound's Q1 earnings report.

MediWound Earnings Preview

MediWound is preparing for NexoBrid's PDUFA date that is scheduled in June of this year. If approved, NexoBrid will be entering a $200M TAM with numerous benefits over the standard-of-care.

MediWound: Managing A Position Ahead Of NexoBrid's PDUFA

YAVNE, Israel, April 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 at 7:00 am Eastern Time on Wednesday, May 5, 2021.

MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021

Data Expected Second-Half 2021 Data Expected Second-Half 2021

MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx

Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time Webinar To Be Held on Tuesday, March 30th at 10am Eastern Time

MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds

MediWound Ltd. (MDWD) CEO Sharon Malka on Q4 2020 Results - Earnings Call Transcript

YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will present at the following virtual investor conferences in March 2021:

MediWound to Participate in Upcoming March Investment Conferences

Fourth Quarter Revenues of $6.7 Million - Up 23% and Full-Year 20 20 Revenues of $ 2 1.8 Million - Product Revenue Up 117%

MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results

Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021

MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer

YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2020 at 7:00 am Eastern Time on Thursday, February 25, 2021.

MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021

YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held February 17-19, 2021.

MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients

MediWound Provides Progress Update on Its EscharEx Clinical Development Program

YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference. Both conferences will take place virtually.

MediWound to Participate in Upcoming Investor Conferences in January

MediWound recently reported an encouraging Q3 with a beat on EPS and revenue. It looks as if the company is easily weathering the pandemic with support from BARDA purchases. I have already established a speculative position ahead of a potential NexoBrid approval. Now, I am looking to stick my MDWD in the back of my sock drawer.

MediWound: A Collectable Investment Worthy Of A Long-Term Hold

Data to be Published in a Peer-Reviewed Journal in First Half 2021 Data to be Published in a Peer-Reviewed Journal in First Half 2021

News for MediWound Stock (MDWD)